Claims for Patent: 8,435,970

Summary for Patent: 8,435,970

Title:	Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea
Abstract:	The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I\') ##STR00001## or a salt, solvate, tautomer or N-oxide thereof, wherein R.sup.1, E, A and M are as defined in the claims.
Inventor(s):	Curry; Jayne Elizabeth (Cambridge, GB), Gallagher; Neil James (Basel, CH), Lyons; John Francis (London, GB), Thompson; Neil Thomas (Cambridge, GB)
Assignee:	Astex Therapeutics Limited (Cambridge, GB)
Application Number:	12/306,479
Patent Claims:	1. A combination comprising an ancillary compound and the compound 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea, or a salt, tautomer or N-oxide thereof, wherein the ancillary compound is selected from: 1. hormones, hormone agonists, hormone antagonists and hormone modulating agents, wherein said hormones, hormone agonists, hormone antagonists and hormone modulating agents are selected from corticosteroids, antiandrogens, antiestrogens and GNRAs; 2. cytokines and cytokine activating agents; 3. retinoids and rexinoids 4. monoclonal antibodies to cell surface antigen(s); 5. camptothecin compounds, wherein the camptothecin compound is selected from camptothecin and topotecan; 6. antimetabolites wherein the antimetabolite is selected from gemcitabine, capecitabine, cytarabine, ralitrexed, pemetrexed and methotrexate; or 6-mercapto purine, 6-thioguanine, cladribine, 2'-deoxycoformycin and hydroxyurea; 7. vinca alkaloids, wherein the vinca alkaloid is selected from vindesine, vinvesir, vinblastine, vincristine and vinorelbine; 8. taxanes, wherein the taxane is selected from paclitaxel and docetaxel; 9. epothilones; 10. platinum compounds, wherein the platinum compound is selected from chloro(diethylenediamino)-platinum (II) chloride; dichloro(ethylenediamino)-platinum (II); spiroplatin; iproplatin; diamino(2-ethylmalonato)platinum (II); (1,2-diaminocyclohexane)malonatoplatinum (II); (4-carboxyphthalo)-(1,2-diaminocyclohexane)platinum (II); (1,2-diaminocyclohexane)-(isocitrato)platinum (II); (1,2-diaminocyclohexane)-cis-(pyruvato)platinum (II); onnaplatin; tetraplatin, carboplatin or oxaliplatin; 11. Topo II inhibitors, wherein said Topo II inhibitors are selected from daunorubicin, idarubicin, epirubicin; or is selected from etoposide a and teniposide; or is mitoxantrone; or is selected from losoxantrone and actinomycin D; 12. alkylating agents wherein said alkylating agents are selected from aziridine, busulfan, nitrogen mustard and nitrosourea alkylating agents; 13. signalling inhibitors, wherein said signalling inhibitor is selected from sunitinib, trastuzumab, cetuximab, gefitinib, erlotinib, bevacizumab, imatinib mesylate, sorafenib, dasatinib, lapatinib, nilotinib, vandetanib, vatalinib, CHIR-258, and axitinib; 14. CDK inhibitors, wherein said CDK inhibitors are ancillary CDK inhibitors; 15. COX-2 inhibitors; 16. HDAC inhibitors; 17. Selective immunoresponse modulators; 18. DNA methyl transferase inhibitors; 19. proteasome inhibitors; 20. Aurora inhibitors, wherein said Aurora inhibitors are ancillary Aurora inhibitors; 21. Hsp90 inhibitors; 22. Checkpoint targeting agents selected from polo-like kinase inhibitors (Plks), CHK kinase inhibitors, inhibitors of the BUB kinase family and kinesin inhibitors; 23. DNA repair inhibitors; and 24. Inhibitors of G-protein coupled receptor. 2. The combination according to claim 1 comprising the compound 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea or a salt thereof. 3. The combination according to claim 1 comprising an ancillary compound and a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. 4. A combination according to claim 1 wherein (A) the ancillary compound and 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-- pyrazol-4-yl]-urea or salt, tautomer or N-oxide thereof are physically associated and are; (a) in admixture; (b) chemically/physicochemically linked; (c) chemically/physicochemically co-packaged; or (d) unmixed but co-packaged or co-presented; or (B) the ancillary compound and 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea or salt, tautomer or N-oxide thereof are non-physically associated. 5. A combination according to claim 1 wherein the combination comprises two or more ancillary compounds. 6. A combination according to claim 1 wherein the ancillary compound is selected from: (a) a taxane compound selected from paclitaxel and docetaxel; (b) an antimetabolic compound selected from gemcitabine, capecitabine, cytarabine, ralitrexed, pemetrexed, and methotrexate; (c) a signalling inhibitor selected from trastuzumab, cetuximab, gefitinib, erlotinib, bevacizumab, imatinib mesylate, sorafenib, dasatinib, lapatinib, nilotinib, vandetanib, vatalinib, axitinib and CHIR-258; (d) a cytokine, cytokine activating agent or retinoid selected from an interferon, an interleukin, tretinoin, alitretinoin and bexarotene. (e) a camptothecin compound selected from camptothecin and topotecan; (f) a vinca alkaloid compound selected from vinorelbine, vinblastine and vincristine; (g) a platinum compound selected from chloro(diethylenediamino)-platinum (II) chloride; dichloro(ethylenediamino)-platinum (II); spiroplatin; iproplatin; diamino(2-ethylmalonato)platinum (II); (1,2-diaminocyclohexane)malonatoplatinum (II); (4-carboxyphthalo)-(1,2-diaminocyclohexane)platinum (II); (1,2-diaminocyclohexane)-(isocitrato)platinum (II); (1,2-diaminocyclohexane)-cis-(pyruvato)platinum (II); onnaplatin; tetraplatin, carboplatin and oxaliplatin; (h) a topoisomerase 2 inhibitor selected from daunorubicin, idarubicin, epirubicin; or is selected from etoposide and teniposide; or is mitoxantrone; or is selected from losoxantrone and actinomycin D; (i) an antiandrogen or an antiestrogen, wherein the antiandrogen is an aromatase inhibitor selected from letrozole, anastrozole, exemestane or aminoglutethimide, or is an antiandrogen selected from tamoxifen, fulvestrant, raloxifene, toremifene, droloxifene, letrazole, anastrazole, exemestane, bicalutamide, luprolide, megestrol acetate, aminoglutethimide and bexarotene; (j) a GnRH analog selected from goserelin and leuprolide; (k) a monoclonal antibody to cell surface antigens (or an anti-CD antibody) selected from CD20, CD22, CD33, CD52, rituximab, tositumomab and gemtuzumab; (l) an alkylating agent selected from a nitrogen mustard compound, nitrosourea compound and busulfan; (m) an HDAC inhibitor selected from TSA, SAHA, JNJ-16241199, LAQ-824, MGCD-0103 and PXD-101; (n) a COX-2 inhibitor which is celecoxib; (o) a DNA methylation inhibitor selected from temozolomide, decitabine and 5-azacitidine; (p) a proteasome inhibitor which is bortezimib; and (q) a CDK inhibitor selected from seliciclib, alvocidib, 7-hydroxystaurosparine, JNJ-7706621, BMS-387032, Pha533533, PD332991, ZK-304709 and AZD-5438. 7. A combination according to claim 1 comprising two or more ancillary compounds independently selected from: an antimetabolic compound, a taxane compound, an epothilone, an Hsp90 inhibitor, a signalling inhibitor, a camptothecin compound, a vinca alkaloid compound, a platinum compound, a topoisomerase 2 inhibitor, an antiandrogen, a monoclonal antibody, an alkylating agent, a histone deacetylase inhibitor (HDAC), a cyclooxygenase-2 (COX-2) inhibitor, a proteasome inhibitor, DNA methylation inhibitor, a CDK inhibitor, an Aurora inhibitor and a checkpoint targeting agent. 8. A combination according to claim 1 comprising one or more checkpoint targeting agents. 9. A combination according to claim 1 comprising one or more ancillary compounds selected from vinblastine, and paclitaxel. 10. A combination according to claim 1 wherein the ancillary compound is an agent for treating multiple myeloma selected from a vinca alkaloid compound, a selective immunoresponse modulator and a proteasome inhibitor. 11. A combination according to claim 1 wherein the ancillary compound is an agent for treating multiple myeloma selected from vincristine, lenalidomide and bortezomib. 12. A combination according to claim 1 wherein the ancillary compound is selected from a vinca alkaloid compound, a selective immunoresponse modulator and a proteasome inhibitor. 13. A combination according to claim 1 wherein the ancillary compound is selected from: paclitaxel, docetaxel, vincristine, lenalidomide and bortezomib. 14. A combination according to claim 2 wherein the ancillary compound is selected from: paclitaxel, docetaxel, vincristine, lenalidomide and bortezomib. 15. A combination according to claim 14 wherein the ancillary compound is lenalidomide.

Details for Patent 8,435,970

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-06-09
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-06-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2026-06-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2026-06-09
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	06/27/2003		2026-06-09